CA3031370A1 - Ophthalmic pharmaceutical compositions and uses relating thereto - Google Patents

Ophthalmic pharmaceutical compositions and uses relating thereto Download PDF

Info

Publication number
CA3031370A1
CA3031370A1 CA3031370A CA3031370A CA3031370A1 CA 3031370 A1 CA3031370 A1 CA 3031370A1 CA 3031370 A CA3031370 A CA 3031370A CA 3031370 A CA3031370 A CA 3031370A CA 3031370 A1 CA3031370 A1 CA 3031370A1
Authority
CA
Canada
Prior art keywords
concentration
pharmaceutical composition
ophthalmic pharmaceutical
pilocarpine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3031370A
Other languages
English (en)
French (fr)
Inventor
Claes Feinbaum
Franc Salamun
Sudhir PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orasis Pharmaceuticals Ltd
Original Assignee
Orasis Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orasis Pharmaceuticals Ltd filed Critical Orasis Pharmaceuticals Ltd
Publication of CA3031370A1 publication Critical patent/CA3031370A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CA3031370A 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto Pending CA3031370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19
US62/377,154 2016-08-19
PCT/IB2017/001140 WO2018033792A2 (en) 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto

Publications (1)

Publication Number Publication Date
CA3031370A1 true CA3031370A1 (en) 2018-02-22

Family

ID=60935566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3031370A Pending CA3031370A1 (en) 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto

Country Status (13)

Country Link
US (6) US9867810B1 (cg-RX-API-DMAC7.html)
EP (2) EP3500255B1 (cg-RX-API-DMAC7.html)
JP (3) JP7297308B2 (cg-RX-API-DMAC7.html)
KR (2) KR102588499B1 (cg-RX-API-DMAC7.html)
CN (2) CN109803652A (cg-RX-API-DMAC7.html)
AU (2) AU2017311636B2 (cg-RX-API-DMAC7.html)
CA (1) CA3031370A1 (cg-RX-API-DMAC7.html)
ES (1) ES2934790T3 (cg-RX-API-DMAC7.html)
IL (2) IL297367A (cg-RX-API-DMAC7.html)
MX (2) MX2019001877A (cg-RX-API-DMAC7.html)
PL (1) PL3500255T3 (cg-RX-API-DMAC7.html)
PT (1) PT3500255T (cg-RX-API-DMAC7.html)
WO (1) WO2018033792A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
PL3681500T3 (pl) * 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US12161629B2 (en) 2018-10-15 2024-12-10 Opus Genetics, Inc. Methods and compositions for treatment of glaucoma and related conditions
CN113164452A (zh) 2018-10-26 2021-07-23 奥库菲尔制药股份有限公司 治疗老花眼、散瞳和其他眼部疾病的方法和组合物
CA3138510A1 (en) * 2019-05-08 2020-11-12 Harrow Ip, Llc Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof
EP4210690B1 (en) * 2020-09-11 2025-01-29 Intratus-Nevada, Inc. Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US11857538B2 (en) 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
EP4471024A4 (en) * 2022-01-29 2025-10-08 Nanjing Gritpharma Co Ltd M-CHOLINE RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
AU2287597A (en) 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
US6274634B1 (en) 1997-05-14 2001-08-14 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020128267A1 (en) 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2839898C (en) 2003-06-13 2017-01-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US8512717B2 (en) * 2003-08-07 2013-08-20 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
US20080145430A1 (en) 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
ATE439863T1 (de) 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
WO2008074865A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Dimeric prolactin receptor ligands
US9855337B2 (en) 2007-01-31 2018-01-02 Alumend, Llc Biomaterials and a method for making and using the same
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
MX2009012645A (es) 2007-05-24 2010-03-08 Aciex Therapeutics Inc Formulaciones y metodos para tratar el ojo seco.
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011079123A1 (en) 2009-12-23 2011-06-30 Alimera Sciences, Inc. Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
UA113525C2 (xx) * 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
AU2014382677A1 (en) * 2014-02-11 2016-09-01 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
WO2018033792A2 (en) * 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto

Also Published As

Publication number Publication date
PL3500255T3 (pl) 2023-03-13
ES2934790T3 (es) 2023-02-27
AU2017311636B2 (en) 2023-08-10
RU2019107585A (ru) 2020-09-21
US20200222369A1 (en) 2020-07-16
US20180318264A1 (en) 2018-11-08
PT3500255T (pt) 2023-01-10
AU2017311636A1 (en) 2019-02-14
JP7297308B2 (ja) 2023-06-26
IL297367A (en) 2022-12-01
KR102472774B1 (ko) 2022-11-30
US10639297B2 (en) 2020-05-05
EP4190328A1 (en) 2023-06-07
AU2023226732A1 (en) 2023-09-28
US20220184039A1 (en) 2022-06-16
US20180207136A1 (en) 2018-07-26
WO2018033792A3 (en) 2018-03-29
BR112019002967A2 (pt) 2019-05-14
RU2019107585A3 (cg-RX-API-DMAC7.html) 2020-12-22
EP3500255A4 (en) 2020-03-25
EP3500255A2 (en) 2019-06-26
US20250268867A1 (en) 2025-08-28
KR20190051973A (ko) 2019-05-15
KR102588499B1 (ko) 2023-10-11
US11974986B2 (en) 2024-05-07
US11129812B2 (en) 2021-09-28
MX2019001877A (es) 2019-09-13
IL264664B (en) 2022-11-01
MX2023003124A (es) 2023-03-22
WO2018033792A2 (en) 2018-02-22
KR20220162876A (ko) 2022-12-08
JP2025168426A (ja) 2025-11-07
JP2019524826A (ja) 2019-09-05
IL264664B2 (en) 2023-03-01
JP2023105147A (ja) 2023-07-28
EP3500255B1 (en) 2022-11-30
CN109803652A (zh) 2019-05-24
US9867810B1 (en) 2018-01-16
IL264664A (cg-RX-API-DMAC7.html) 2019-03-31
CN116726006A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
US11974986B2 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
Grzybowski et al. A review of pharmacological presbyopia treatment
Cameron et al. Laser in situ keratomileusis–induced optic neuropathy
ES2920803T3 (es) Uso de clorhidrato de pilocarpina para el tratamiento de la presbicia
DK2874660T3 (en) Ophthalmic formulation and approach to improving presbyopia
BRPI0821683B1 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
Renna et al. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: a pilot study
Montés-Micó et al. Pharmacological strategies for presbyopia correction
Lee et al. Measurement of contrast sensitivity and glare under mesopic and photopic conditions following wavefront-guided and conventional LASIK surgery
Holland et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials
Orman et al. Overview of pharmacological treatments for presbyopia
HK40094546A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
RU2791371C2 (ru) Офтальмологические фармацевтические композиции и их применение
HK40002937B (en) Ophthalmic pharmaceutical compositions and uses relating thereto
HK40002937A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
BR112019002967B1 (pt) Composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, implante, e, kit
Bishop et al. Ophthalmology cystinosis fórum afternoon sesión
Lakhanpal Vani Vidya Sagar Alka A One Year Hospital Based Cross Sectional Study Of The Association Between The Pattern Of Myopic Fundal Changes And The Axis Of Astigmatism Of The Eye
HK40012326A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
SCHWEITZER Shrinking Night Vision Disturbances

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817

EEER Examination request

Effective date: 20220817